Shandong Pharmaceutical Group announced that the 11th meeting of the company's 11th board of directors reviewed and passed a number of proposals: first, to pass the 2026 third quarter report; second, to revise the 2026 sale limit schedule for the issuance of A-shares to specific targets and to update the fixed increase plan and prospectus simultaneously; third, to sign a supplementary agreement with the issuer to enter into force conditionally. This fixed increase constitutes a related transaction and does not constitute a major asset restructuring; fourth, to increase the 2026 daily related transaction forecast. Directors Zhang Taigang and Feng Jiayou avoided voting on the bill relating to the above related transactions. This fixed increase still needs to be reviewed by the Shanghai Stock Exchange and approved by the Securities Regulatory Commission for registration, and the final results are uncertain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.